PD-L1-related LncRNAs are Associated with Immune Microenvironment and Prognosis in Glioma

Abstract

Abstract Background The expression of long non-coding RNAs (lncRNAs) can function as diagnostic and therapeutic biomarkers of tumours, this research explored the effects of programmed cell death ligand-1(PD-L1) related lncRNAs on glioma. Methods Downloading gene expression profiles and clinicopathological information of glioma from TCGA and CGGA databases, 6 PD-L1-related lncRNAs were screened out through correlation analysis, Cox and LASSO regression analysis. The risk score model was established based on 6 PD-L1-related lncRNAs. Using GSVA and GSEA analyses to investigate the biological function. LINC01271 was selected as the target, and bioinformatics analysis and cell experiments in vitro were adopted to verify its effects on glioma. Results Risk scores based on 6 PD-L1-related lncRNAs (AL355974.3, LINC01271, AC011899.3, MIR4500HG, LINC02594, AL357055.3) can predict the prognosis of glioma(LGG and GBM). The high-risk score group has more typical malignant features in the immune-inflammatory microenvironment and is prone to be sensitive to anti-PD-1 treatment. The nomogram combining these lncRNAs and clinical parameters has good forecasting efficiency. LINC01271 expression can be used as a risk stratification index of glioma. Experiments in vitro confirmed its positive regulatory effect on the proliferation and migration of glioma cells. Conclusions This study demonstrates the predictive value of the risk score model based on 6 PD-L1-related lncRNAs for glioma characteristics, prognosis and immunotherapy responsiveness. LncRNA LINC01271 can independently be used as a new target for prognosis evaluation and therapy of glioma.